Abstract: FR-PO1107
Safety and Efficacy of One and Two Booster Doses of SARS-CoV-2 mRNA Vaccines in Kidney Transplant Recipients: A Randomized Clinical Trial
Session Information
- COVID-19 - II
November 03, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Coronavirus (COVID-19)
- 000 Coronavirus (COVID-19)
Authors
- Drenko, Petr, Department of Internal Medicine I, Faculty of Medicine in Pilsen, Charles University, and University Hospital, Pilsen, Czechia
- Kacer, Martin, Department of Internal Medicine I, Faculty of Medicine in Pilsen, Charles University, and University Hospital, Pilsen, Czechia
- Kielberger, Lukas, Department of Internal Medicine I, Faculty of Medicine in Pilsen, Charles University, and University Hospital, Pilsen, Czechia
- Vlas, Tomas, Department of Immunology and Allergology, Faculty of Medicine in Pilsen, Charles University, and University Hospital, Pilsen, Czechia
- Kucera, Radek, Department of Immunochemistry Diagnostics, Faculty of Medicine in Pilsen, Charles University, and University Hospital, Pilsen, Czechia
- Reischig, Tomas, Department of Internal Medicine I, Faculty of Medicine in Pilsen, Charles University, and University Hospital, Pilsen, Czechia
Background
Kidney transplant recipients are at risk for a severe course of COVID-19 with a high mortality rate. Although an adequate humoral response to COVID-19 vaccination is therefore essential, a considerable number of patients remains without a satisfactory serological response after the baseline and adjuvant SARS-CoV-2 vaccination schedule.
Methods
In this prospective, randomized study, we evaluated the efficacy and safety of one and two booster doses of mRNA vaccines (either mRNA-1273 or BNT162b2) in 125 COVID-19 naive, adult kidney transplant recipients who showed an insufficient humoral response (SARS-CoV-2 IgG <10 AU/ml) to the previous 2-dose vaccination schedule. The primary outcome was the occurrence of a positive antibody response between one and two booster doses at one month after the final booster dose.
Results
A positive humoral response was observed in 36 (62%) patients who received two booster doses and in 28 (44%) patients who received one booster dose (p=.043). Moreover, median SARS-CoV-2 IgG levels were higher with two booster doses (p=.009). The number of patients with positive virus neutralizing antibody levels was numerically higher in the two booster doses compared to the single booster dose, but without statistical significant (66% vs. 50%, p=.084). There was no significant difference in the rate of positive seroconversion and antibody levels between mRNA-1273 and BNT162b2 vaccines.
Conclusion
A higher number of kidney transplant recipients achieved a positive antibody response after two booster doses compared to one booster dose.
Funding
- Other NIH Support